Allostery Investments LP Buys New Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Allostery Investments LP purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 479,100 shares of the specialty pharmaceutical company's stock, valued at approximately $4,058,000. KalVista Pharmaceuticals accounts for about 4.2% of Allostery Investments LP's investment portfolio, making the stock its 6th biggest holding. Allostery Investments LP owned 0.97% of KalVista Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Aquatic Capital Management LLC acquired a new stake in KalVista Pharmaceuticals during the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC lifted its position in KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after acquiring an additional 5,502 shares in the last quarter. Legal & General Group Plc boosted its stake in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 1,494 shares during the period. Martin Worley Group acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $86,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after purchasing an additional 2,043 shares in the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average price of $9.42 per share, for a total transaction of $235,500.00. Following the completion of the transaction, the insider now owns 5,303,985 shares of the company's stock, valued at approximately $49,963,538.70. This trade represents a 0.47 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Paul K. Audhya sold 3,125 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares in the company, valued at approximately $985,279.88. This represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 202,786 shares of company stock worth $1,880,511 and sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock traded down $0.01 during mid-day trading on Wednesday, hitting $12.49. 111,066 shares of the company's stock traded hands, compared to its average volume of 411,607. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The stock has a market cap of $620.70 million, a price-to-earnings ratio of -3.43 and a beta of 0.05. The firm has a 50 day simple moving average of $11.99 and a two-hundred day simple moving average of $10.42.

Analysts Set New Price Targets

Several equities research analysts have commented on KALV shares. TD Cowen assumed coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating and a $30.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Jones Trading reissued a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).